BTX AgilePulse™ system is an effective electroporation device for intramuscular and intradermal delivery of DNA vaccine

Current Gene Therapy

Volumn 14, Issue 3, 2014, Pages 190-199

  Davtyan, Hayk ^a   Hovakimyan, Armine ^a   Zagorski, Karen ^a   Davtyan, Arpine ^a   Petrushina, Irina ^b   Agdashian, David ^a   Murthy, Vidya ^c   Cribbs, David H ^b   Agadjanyan, Michael G ^a,b   Ghochikyan, Anahit ^a  

^a INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Harvard Apparatus Inc   (United States)

Author keywords

AV 1959D vaccine; Electroporation device; Immune responses; Intradermal delivery; Intramuscular delivery; Optimization of BTX AgilePulse system; Plasmid immunizations

Indexed keywords

ANTIBODY; CYTOKINE; DNA VACCINE; EPITOPE; RECOMBINANT PROTEIN; ALZHEIMER DISEASE VACCINE; AV 1959D; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; INTERLEUKIN 4; UNCLASSIFIED DRUG;

ANIMAL; C57BL MOUSE; CELL PROLIFERATION; CELLULAR IMMUNITY; DEVICES; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ELECTROPORATION; FEMALE; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; PLASMID; PROCEDURES; T LYMPHOCYTE; VACCINATION; AGAR GEL ELECTROPHORESIS; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CYTOKINE PRODUCTION; DNA IMMUNIZATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; GENE DELIVERY SYSTEM; GENE EXPRESSION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; SPLEEN CELL;

ANIMALS; ANTIBODIES; CELL PROLIFERATION; CYTOKINES; DRUG DELIVERY SYSTEMS; ELECTROPORATION; EPITOPES, B-LYMPHOCYTE; FEMALE; IMMUNITY, CELLULAR; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED C57BL; PLASMIDS; RECOMBINANT PROTEINS; T-LYMPHOCYTES; VACCINATION; VACCINES, DNA;

ANIMALIA;

EID: 84906913657     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523214666140522121427     Document Type: Article

References (71)

1. Ugen KE, Kutzler MA, Marrero B, et al. Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in vivo electroporation. Cancer Gene Ther 2006;13(10):969-74.
2. Abdulhaqq SA, Weiner DB. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res 2008;42(1-3):219-32.
3. Agadjanyan MG, Wang B, Nyland SB, Weiner DB, Ugen KE. DNA plasmid based vaccination against the oncogenic human T cell leukemia virus type 1. Curr Top Microbiol Immunol 1998;226(3):175-92.
4. Kim JJ, Nottingham LK, Wilson DM, et al. Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes. Vaccine 1998;16(19):1828-35.
5. Ghochikyan A, Vasilevko V, Petrushina I, et al. Generation and chracterization of the humoral immune response to DNA immunization with a chimeric b-amyloid-interleukin-4 minigene. Eur J Immunol 2003;33(12):3232-41.
6. Ghochikyan A. Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy. CNS Neurol Disord Drug Targets 2009;8(2):128-43.
7. Li L, Saade F, Petrovsky N. The future of human DNA vaccines. J Biotechnol 2012;162(2-3):171-82.
8. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992;356(6365):152-4.
9. Wang B, Ugen KE, Srikantan V, et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90(9):4156-60.
10. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-49.
11. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A 1993;90(24):11478-82.
12. Felgner PL. DNA vaccines. Curr Biol 1998;8(16):R551-3.
13. MacGregor RR, Boyer JD, Ugen KE, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998;178(1):92-100.
14. Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical applications of DNA vaccines: current progress. Clin Infect Dis 2011;53(3):296-302.
15. Babiuk LA, Pontarollo R, Babiuk S, Loehr B, van Drunen Littel-van den Hurk S. Induction of immune responses by DNA vaccines in large animals. Vaccine 2003;21(7-8):649-58.
16. Gregersen JP. DNA vaccines. Naturwissenschaften 2001;88(12):504-13.
17. Cribbs DH, Agadjanyan MG. Immunotherapy for Alzheimer's Disease: Potential Problems and Possible Solutions. Curr Immunol Rev 2005;1(2):139-155.
18. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008;9(10):776-88.
19. Fuller DH, Corb MM, Barnett S, Steimer K, Haynes JR. Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques. Vaccine 1997;15(8):924-6.
20. Torres CA, Iwasaki A, Barber BH, Robinson HL. Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. J Immunol 1997;158(10):4529-32.
21. Roy MJ, Wu MS, Barr LJ, et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000;19(7-8):764-78.
22. McCray AN, Ugen KE, Muthumani K, Kim JJ, Weiner DB, Heller R. Complete regression of established subcutaneous B16 murine melanoma tumors after delivery of an HIV-1 Vpr-expressing plasmid by in vivo electroporation. Mol Ther 2006;14(5):647-55.
23. Luxembourg A, Evans CF, Hannaman D. Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol Ther 2007;7(11):1647-64.
24. Roos AK, Moreno S, Leder C, Pavlenko M, King A, Pisa P. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther 2006;13(2):320-7.
25. Haensler J, Verdelet C, Sanchez V, et al. Intradermal DNA immunization by using jet-injectors in mice and monkeys. Vaccine 1999;17(7-8):628-38.
26. Walther W, Stein U, Fichtner I, Schlag PM. Low-volume jet injection for efficient nonviral in vivo gene transfer. Mol Biotechnol 2004;28(2):121-8.
27. Gregoriadis G, Saffie R, de Souza JB. Liposome-mediated DNA vaccination. FEBS Lett 1997;402(2-3):107-10.
28. Jones DH, Corris S, McDonald S, Clegg JC, Farrar GH. Poly(DLlactideco-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine 1997;15(8):814-7.
29. Hedley ML, Curley J, Urban R. Microspheres containing plasmidencoded antigens elicit cytotoxic T-cell responses. Nat Med 1998;4(3):365-8.
30. O'Hagan D, Singh M, Ugozzoli M, et al. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J Virol 2001;75(19):9037-43.
31. Greenland JR, Geiben R, Ghosh S, Pastor WA, Letvin NL. Plasmid DNA vaccine-elicited cellular immune responses limit in vivo vaccine antigen expression through Fas-mediated apoptosis. J Immunol 2007;178(9):5652-8.
32. Flingai S, Czerwonko M, Goodman J, Kudchodkar SB, Muthumani K, Weiner DB. Synthetic DNA Vaccines: Improved Vaccine Potency by Electroporation and Co-Delivered Genetic Adjuvants. Front Immunol 2013;4:354.
33. Movsesyan N, Ghochikyan A, Mkrtichyan M, et al. Reducing ADlike pathology in 3xTg-AD mouse model by DNA epitope vaccinea novel immunotherapeutic strategy. PLos ONE 2008;3(5):e21-4.
34. Davtyan H, Mkrtichyan M, Movsesyan N, et al. DNA primeprotein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther 2010;17(2):261-71.
35. Davtyan H, Ghochikyan A, Movsesyan N, et al. Delivery of a DNA Vaccine for Alzheimer's Disease by Electroporation versus Gene Gun Generates Potent and Similar Immune Responses. Neurodegener Dis 2012;10(1-4):261-4.
36. Hurk S, Hannaman D. Electroporation for DNA immunization: clinical application. Expert Rev Vaccines 2010;9(5):503-17.
37. Chudley L, McCann K, Mander A, et al. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. Cancer Immunol Immunother 2012;61(11):2161-70.
38. Bagarazzi ML, Yan J, Morrow MP, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 2012;4(155):155ra138.
39. Gothelf A, Gehl J. What you always needed to know about electroporation based DNA vaccines. Hum Vaccin Immunother 2012;8(11):1694-702.
40. Ghochikyan A, Davtyan H, Petrushina I, et al. Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits. Hum Vaccin Immunother 2013;9(5):1002-10.
41. Evans CF, Davtyan H, Petrushina I, et al. Epitope-based DNA vaccine for Alzheimer's disease: Translational study in macaques. Alzheimers Dement 2014;10(3):284-95.
42. Davtyan H, Ghochikyan A, Petrushina I, et al. The MultiTEP platform-based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates. Alzheimers Dement 2014;10(3):271-83.
43. Roos AK, Eriksson F, Timmons JA, et al. Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One 2009;4(9):e7226.
44. Olkhanud PB, Mughal M, Ayukawa K, et al. DNA immunization with HBsAg-based particles expressing a B cell epitope of amyloid beta-peptide attenuates disease progression and prolongs survival in a mouse model of Alzheimer's disease. Vaccine 2012;30(9):1650-8.
45. Movsesyan N, Mkrtichyan M, Petrushina I, et al. DNA epitope vaccine containing complement component C3d enhances antiamyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype. J Neuroimmunol 2008;205(1-2):57-63.
46. Agadjanyan MG, Ghochikyan A, Petrushina I, et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 2005;174(3):1580-6.
47. Petrushina I, Ghochikyan A, Mktrichyan M, et al. Alzheimer's Disease Peptide Epitope Vaccine Reduces Insoluble But Not Soluble/Oligomeric A{beta} Species in Amyloid Precursor Protein Transgenic Mice. J Neurosci 2007;27(46):12721-31.
48. Gabriel B, Teissie J. Direct observation in the millisecond time range of fluorescent molecule asymmetrical interaction with the electropermeabilized cell membrane. Biophys J 1997;73(5):2630-7.
49. Andreason GL, Evans GA. Optimization of electroporation for transfection of mammalian cell lines. Anal Biochem 1989;180(2):269-75.
50. Satkauskas S, Bureau MF, Puc M, et al. Mechanisms of in vivo DNA electrotransfer: respective contributions of cell electropermeabilization and DNA electrophoresis. Mol Ther 2002;5(2):133-40.
51. McCluskie MJ, Brazolot Millan CL, Gramzinski RA, et al. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol Med 1999;5(5):287-300.
52. Banga AK, Prausnitz MR. Assessing the potential of skin electroporation for the delivery of protein- and gene-based drugs. Trends Biotechnol 1998;16(10):408-12.
53. Widera G, Austin M, Rabussay D, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000;164(9):4635-40.
54. Hallengard D, Applequist SE, Nystrom S, et al. Immunization with multiple vaccine modalities induce strong HIV-specific cellular and humoral immune responses. Viral Immunol 2012;25(5):423-32.
55. Davtyan H, Ghochikyan A, Petrushina I, et al. Immunogenicity, Efficacy, Safety, and Mechanism of Action of Epitope Vaccine (Lu AF20513) for Alzheimer's Disease: Prelude to a Clinical Trial. J Neurosci 2013;33(11):4923-34.
56. Babiuk S, Baca-Estrada M, Babiuk LA, Ewen C, Foldvari M. Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. J Control Release 2000;66(2-3):199-214.
57. Hallengard D, Haller BK, Maltais AK, et al. Comparison of plasmid vaccine immunization schedules using intradermal in vivo electroporation. Clin Vaccine Immunol 2011;18(9):1577-81.
58. Gothelf A, Eriksen J, Hojman P, Gehl J. Duration and level of transgene expression after gene electrotransfer to skin in mice. Gene Ther 2010;17(7):839-45.
59. Hojman P, Gissel H, Gehl J. Sensitive and precise regulation of haemoglobin after gene transfer of erythropoietin to muscle tissue using electroporation. Gene Ther 2007;14(12):950-9.
60. Khan AS, Broderick KE, Sardesai NY. Clinical development of intramuscular electroporation: providing a boost for DNA vaccines. Methods Mol Biol 2014;1121:279-89.
61. ClinicalTrials.gov. Identifier: NCT01324843; NCT01697007; NCT00859729; NCT01064375
62. Brave A, Gudmundsdotter L, Sandstrom E, et al. Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation. Vaccine 2010;28(51):8203-9.
63. Hirao LA, Draghia-Akli R, Prigge JT, et al. Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis 2011;203(1):95-102.
64. Laddy DJ, Yan J, Khan AS, et al. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol 2009;83(9):4624-30.
65. Huber VC, McKeon RM, Brackin MN, et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 2006;13(9):981-90.
66. Bard F, Barbour R, Cannon C, et al. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A 2003;100(4):2023-8.
67. Adolfsson O, Pihlgren M, Toni N, et al. An effector-reduced antibeta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J Neurosci 2012;32(28):9677-89.
68. Garber K. Genentech's Alzheimer's antibody trial to study disease prevention. Nat Biotechnol 2012;30(8):731-2.
69. Tao MH, Smith RI, Morrison SL. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med 1993;178(2):661-7.
70. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012;119(24):5640-9.
71. Lambracht-Washington D, Rosenberg RN. Advances in the development of vaccines for Alzheimer's disease. Discov Med 2013;15(84):319-26.